Literature DB >> 9892573

Effects of captopril on fibrinolytic function in healthy humans.

K Lottermoser1, B Wöstmann, B Weisser, H J Hertfelder, U Schmitz, H Vetter, R Düsing.   

Abstract

Several lines of evidence point to an interrelation of the renin angiotensin system (RAS) with the endogenous fibrinolytic system. In the present study, we have therefore investigated the effect of the ACE-inhibitor captopril on various parameters of the fibrinolytic system in healthy volunteer subjects. 10 male subjects aged 28-38 years were given captopril 25 mg b.i.d. over 2 weeks. Venous blood was drawn before and at the end of the treatment period at 09.00 AM, after the volunteers had received their last dose of captopril by 07. 30 AM. Blood samples were processed for the determination of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). Both parameters were determined with respect to their abundance (as antigen concentrations) and function (activity). In addition, the concentration and activity of the von Willebrand factor were also determined. Two weeks of captopril treatment had no significant effect on any of the above mentioned parameters. Our results thus show that short-term treatment with the ACE-inhibitor captopril, at least in healthy subjects on an unrestricted NaCl intake, does not affect the fibrinolytic balance between t-PA and PAI-1 or the von Willebrand factor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892573

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  2 in total

Review 1.  Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells.

Authors:  Garry X Shen
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

2.  Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients.

Authors:  Michael M Hirschl; Andreas Bur; Christian Woisetschlaeger; Ulla Derhaschnig; Anton N Laggner
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-06       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.